6677 Stock Overview
Anxo Pharmaceutical Co., Ltd., a specialty pharmaceutical company, develops, manufactures, and sells pharmaceutical products for medical professionals and patients in Taiwan and internationally.
Anxo Pharmaceutical Co., Ltd. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||NT$20.70|
|52 Week High||NT$26.25|
|52 Week Low||NT$16.30|
|1 Month Change||-3.72%|
|3 Month Change||6.15%|
|1 Year Change||-5.50%|
|3 Year Change||-34.14%|
|5 Year Change||n/a|
|Change since IPO||-56.94%|
Recent News & Updates
These 4 Measures Indicate That Anxo Pharmaceutical (GTSM:6677) Is Using Debt Extensively
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
|6677||TW Pharmaceuticals||TW Market|
Return vs Industry: 6677 underperformed the TW Pharmaceuticals industry which returned 19.5% over the past year.
Return vs Market: 6677 exceeded the TW Market which returned -18.3% over the past year.
|6677 Average Weekly Movement||5.6%|
|Pharmaceuticals Industry Average Movement||5.4%|
|Market Average Movement||5.1%|
|10% most volatile stocks in TW Market||8.2%|
|10% least volatile stocks in TW Market||2.4%|
Stable Share Price: 6677 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 6677's weekly volatility (6%) has been stable over the past year.
About the Company
Anxo Pharmaceutical Co., Ltd., a specialty pharmaceutical company, develops, manufactures, and sells pharmaceutical products for medical professionals and patients in Taiwan and internationally. It offers prescription and over the counter drugs in various therapeutic areas, such as cardiovascular, metabolism, CNS, diabetic, gastroenterology, respiratory, anti-infection, dermatology, nephrology, urology, orthopedics, etc. The company was founded in 2003 and is headquartered in Taipei, Taiwan.
Anxo Pharmaceutical Co., Ltd. Fundamentals Summary
|6677 fundamental statistics|
Is 6677 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|6677 income statement (TTM)|
|Cost of Revenue||NT$500.05m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.44|
|Net Profit Margin||-2.65%|
How did 6677 perform over the long term?See historical performance and comparison